Fusion Antibodies
Fusion Antibodies is a high quality European CRO that offers a range of fee-for-service, royalty free services covering all stages of preclinical therapeutic and diagnostic antibody development.We want to use our next generation CDRx Antibody Humanization Platform to partner with companies interested in developing high quality antibody leads.
We also offer a range of cell line development services and have the associated expertise and partners to deliver a high quality CHO cell line expression for your protein of interest from proof-of-concept to cGMP. Fusion Antibodies also specialize in high quality monoclonal antibodies (particularly those which are difficult to produce), Antibody Sequencing and other Antibody engineering project (scFv, F(ab), chimerics etc). We have the capacity to act as a 1-stop shop, guiding your project from discovery to validation to the clinic.
Contact Fusion Antibodies via their website
News archive
22/04/2020 Fusion Antibodies: Overcoming obstacles on the path to the clinic...more
16/04/2020 Fusion Antibodies and Queen‘s University Belfast new COVID-19 research alliance...more
27/02/2020 Fusion Antibodies: The challenges of phage display for affinity maturation...more
13/02/2020 Fusion Antibodies and Queen‘s University Belfast launch 3rd KTP collaboration...more
22/01/2020 Fusion Antibodies and E2DG announce strategic collaboration...more
29/11/2019 Fusion Antibodies pour expertise into creating RAMP™...more
12/11/2019 Fusion Antibodies In silico – the future of antibody development...more
12/11/2019 Fusion Antibodies strategic collaboration with E2DG...more
08/08/2019 Fusion Antibodies Discuss De-risking Antibody Development...more
08/08/2019 Fusion Antibodies granted CIR approval...more
31/05/2019 Fusion Antibodies celebrates Antibody Humanization Milestone...more
18/02/2019 Fusion Antibodies announces unique Antibody Developability by Design platform (ADD™)...more
16/01/2019 Fusion Antibodies partner with ERADA on Malaria diagnostic...more
21/08/2018 Fusion Antibodies introduces new service: A.D.D.™ platform...more
11/07/2018 Fusion Antibodies' humanized JF5 antibody detects Aspergilus...more
05/06/2018 Fusion Antibodies announces partnership with Protein Alternatives of Spain...more
31/05/2018 Fusion Antibodies case study: biomarkers for bladder and colon cancer...more
25/05/2018 Fusion Antibodies to double workforce with Invest NI help...more
11/04/2018 Meet Fusion Antibodies at Spring 2018 events...more
09/02/2018 February discounts from Fusion Antibodies...more
16/01/2018 Fusion Antibodies announce new services launching in 2018...more
18/12/2017 Fusion Antibodies raises £5.5m on AIM...more
12/12/2017 Fusion Antibodies to seek AIM IPO...more
02/11/2017 Meet Fusion Antibodies at PEGS Europe in Lisbon...more
17/10/2017 Meet Fusion Antibodies at BIO-Europe 2017...more
12/12/2016 Fusion Antibodies supported by Invest NI to double its workforce...more
13/10/2016 Fusion Antibodies and BizCom Japan Continue To Strengthen Ties...more
23/08/2016 Fusion Antibodies Welcomes Human Antibodies & Hybridoma Conference to Belfast...more
05/08/2016 Fusion Antibodies' Paul Kerr discusses Antibody Humanization with PharmaTV...more
16/06/2016 Fusion Antibodies announces cell line partnership with Swiss CDMO Celonic...more
25/05/2016 Fusion Antibodies Announces Second Collaboration with Aerpio Therapeutics...more
19/04/2016 Fusion Antibodies Announce In-Licensing of Anti-AM2R Monoclonal Antibody...more
31/03/2016 Fusion Antibodies and MAB Discovery Announce Project Collaboration...more
24/02/2016 Fusion Antibodies Awarded Crescent Capital Green Bar Award...more
29/01/2016 Fusion Antibodies Blog: Why is Antibody Humanization Still Important?...more
28/09/2015 Fusion Antibodies Fsn1006h Bispecific Antibody Awarded European Patent ...more
09/09/2015 Fusion Antibodies and Clarity Pharmaceuticals (Aus) sign exclusive licensing agreement...more
07/09/2015 Fusion Antibodies Blog: the history of antibodies...more
01/06/2015 Fusion Antibodies featured in EBR Magazine...more
05/02/2015 Fusion Antibodies shortlisted for Irish Times InterTradeIreland Innovation Award...more
05/01/2015 Fusion Antibodies forthcoming events attendance...more
13/10/2014 Fusion Antibodies Develop Stable Cell Line for ISCA Diagnostics...more
08/10/2014 Fusion Antibodies and ISCA Diagnostics announce humanized Aspergillus MAb JF5...more
24/09/2014 Fusion Antibodies collaboration with Japan’s Chiome Bioscience...more
04/09/2014 Fusion Science:Monoclonal Antibodies Review...more
02/07/2014 Score with Fusion Antibodies...more
20/05/2014 Fusion Antibodies announces collaboration with regenerative medicine company Avipero...more
15/05/2014 Fusion Antibodies lead drug targets Pancreatic Cancer...more
25/03/2014 Fusion Antibodies: New pricing, new services, same quality...more
18/02/2014 Fusion Antibodies and Pepscan Announce Collaboration...more
30/01/2014 Fusion Antibodies announce F.A.A.S.T. Sequencing Service...more
13/01/2014 BizCom Japan and Fusion Antibodies Agree Distribution and Marketing Agreement...more
25/11/2013 Fusion Antibodies to develop technology services to support international research teams...more
